Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA approval for Crestor

Aug. 20, 2003

Novel PDE7B inhibitors with utility in osteoporosis therapy claimed by Bayer

Aug. 19, 2003

Lilly returns rhGH program rights to Emisphere

Aug. 19, 2003

Novel 5-HT2C receptor ligands and their use as antiobesity agents

Aug. 13, 2003

First pivotal exenatide study produces positive results

Aug. 12, 2003

E.U. orphan drug status awarded to Fidelin for adrenal insufficiency

Aug. 11, 2003

EP2 receptor agonist CP-533536 offers a therapeutic alternative for bone fractures and defects

Aug. 11, 2003

Irreversible inhibition of CYP3A4 described for tabimorelin in humans

Aug. 6, 2003

Two novel series of lanosterol synthase inhibitors in early development at Roche

Aug. 6, 2003

FDA requests additional information in support of Hemopure BLA

Aug. 6, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...